The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition | Zendy

Charlotte Fischer | Zendy; Viktoria Mans | Zendy; Maren Horn | Zendy; Sabine Naxer | Zendy; Alexa Klettner | Zendy; Christian van Oterendorp | Zendy

Open Access

The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition

Author(s) -

Charlotte Fischer,

Viktoria Mans,

Maren Horn,

Sabine Naxer,

Alexa Klettner,

Christian van Oterendorp

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-19938

Subject(s) - mortise and tenon , vascular endothelial growth factor , bevacizumab , vascular endothelial growth factor a , vegf receptors , cancer research , chemistry , microbiology and biotechnology , medicine , biology , engineering , chemotherapy , structural engineering

Vascular endothelial growth factor-signaling in human tenon fibroblasts (hTFs) has recently become a target for antifibrotic treatment in glaucoma filtration surgery. The anti-VEGF antibody bevacizumab (BVC) has been shown to increase filtration bleb size. Given the relatively high concentration of BVC needed to obtain an effect, we investigated whether BVC acts through VEGF inhibition or via non-antigen-dependent ways.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research